ArticleJHEP reports : innovation in hepatology2025

Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.

Ignazio Piseddu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.